Introduction: Molecular analysis plays a growing role in the diagnosis of mesenchymal neoplasms. The aim of this study was to retrospectively apply broad, multiplex molecular assays (a solid tumor targeted next-generation sequencing [NGS]) assay and single nucleotide polymorphism [SNP] microarray) to selected tumors, exploring the current utility and limitations. Methods: We searched our database (2010-2020) for diagnostically challenging mesenchymal neoplasms. After histologic review of available slides, tissue blocks were selected for NGS, SNP microarray, or both. DNA and RNA were extracted using the AllPrep DNA/RNA FFPE Kit Protocol on the QIAcube instrument. The NGS platform used was the TruSight Tumor 170 (TST-170). For SNP array, copy number variant (CNV) analysis was performed using the OncoScanTM CNV Plus Assay. Results: DNA/RNA was successfully extracted from 50% of tumors (n = 10/20). Specimens not successfully extracted included 6 core biopsies, 3 incisional biopsies, and 1 resection; 4 were decalcified (3 hydrochloric acid, 1 ethylenediaminetetraacetic acid). Higher tumor proportion and number of tumor cells were parameters positively associated with sufficient DNA/RNA extraction whereas necrosis and decalcification were negatively associated with sufficient extraction. Molecular testing helped reach a definitive diagnosis in 50% of tumors (n = 5/10). Conclusions: Although the overall utility of this approach is limited, these molecular panels can be helpful in detecting a specific “driver” alteration.
BirginEYangCHetjensS, et al.Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: a systematic review and meta-analysis. Cancer. 2020;126(9):1917-1928.
2.
ChambersMO’HernKKerrDA. Fine-needle aspiration biopsy for the diagnosis of bone and soft tissue lesions: a systematic review and meta-analysis. J Am Soc Cytopathol. 2020;9(5):429-441.
DoddLGWarePDuncanD, et al.Doing more with less: new markers for sarcoma diagnosis and their applicability to cytology specimens. Diagn Cytopathol. 2016;44(4):351-360.
5.
JoVYDoyleLA. Refinements in sarcoma classification in the current 2013 world health organization classification of tumours of soft tissue and bone. Surg Oncol Clin N Am. 2016;25(4):621-643.
6.
The WHO Classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and bone tumours. 5th ed. IARC Press; 2020.
7.
LamSWCleton-JansenAMClevenAHG, et al.Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing. J Mol Diagn. 2018;20(5):653-663.
8.
StacchiottiSFrezzaAMBlayJY, et al.Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021;127(16):2934-2942.
9.
YatabeY. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010;29(1):23-36.
10.
MotoiNSzokeJRielyGJ, et al.Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827.
11.
HannaNHRobinsonAGTeminS, et al.Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040-1091.
KalemkerianGPNarulaNKennedyEB, et al.Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911-919.
JungHSLeffertsJATsongalisGJ. Utilization of the oncoscan microarray assay in cancer diagnostics. Appl Cancer Res. 2017;37(1):1.
16.
LiMMDattoMDuncavageEJ, et al.Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23.
17.
HeinzeGSchemperM. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409-2419.
18.
BürknerPC. Brms: an R package for Bayesian multilevel models using Stan. J Stat Softw. 2017;80(1):1-28.
19.
MakowskiDBen-ShacharMSLüdeckeD. Bayestestr: describing effects and their uncertainty, existence and significance within the Bayesian framework. J Open Source Softw. 2019;4(40):1541.
20.
LenthRSingmannHLoveJ, et al.Emmeans: estimated marginal means, aka least-squares means. R Package Version. 2018;1(1):3.
21.
IhakaRGentlemanR. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299-314.
22.
ChebibITaylorMSNardiV, et al.Clinical utility of anchored multiplex solid fusion assay for diagnosis of bone and soft tissue tumors. Am J Surg Pathol. 2021;45(8):1127-1137.
23.
MantillaJGRicciottiRWChenE, et al.Detecting disease-defining gene fusions in unclassified round cell sarcomas using anchored multiplex PCR/targeted RNA next-generation sequencing-molecular and clinicopathological characterization of 16 cases. Genes Chromosomes Cancer. 2019;58(10):713-722.
24.
Mariño-EnríquezABovéeJVMG. Molecular pathogenesis and diagnostic, prognostic and predictive molecular markers in sarcoma. Surg Pathol Clin. 2016;9(3):457-473.
25.
CroceSChibonF. Molecular prognostication of uterine smooth muscle neoplasms: from CGH array to CINSARC signature and beyond. Genes Chromosomes Cancer. 2021;60(3):129-137.
26.
de AndreaCESan-JulianMBovéeJVMG. Integrating morphology and genetics in the diagnosis of cartilage tumors. Surg Pathol Clin. 2017;10(3):537-552.
27.
JosephNMMcGillKCHorvaiAE. Genomic profiling of low-grade intramedullary cartilage tumors can distinguish enchondroma from chondrosarcoma. Am J Surg Pathol. 2021;45(6):812-819.
28.
BassBPEngelKBGreytakSR, et al.A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?Arch Pathol Lab Med. 2014;138(11):1520-1530.
29.
NeubauerANeubauerBHeM, et al.Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene. 1992;7(5):1019-1025.
30.
AlersJCKrijtenburgPJVissersKJ, et al.Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization: EDTA is highly preferable to a routinely used acid decalcifier. J Histochem Cytochem. 1999;47(5):703-709.
31.
SchrijverWAMEvan der GroepPHoefnagelLDC, et al.Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Mod Pathol. 2016;29(12):1460-1470.
LazarAJTuvinDHajibashiS, et al.Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518-1527.
34.
ColomboCMiceliRLazarAJ, et al.CTNNB1 45f mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696-3702.
35.
MarchisMLDTonelliFQuaresminiD, et al.Desmoid tumors in familial adenomatous polyposis. Anticancer Res. 2017;37(7):3357-3366.
36.
BhattacharyaBDilworthHPIacobuzio-DonahueC, et al.Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29(5):653-659.
37.
AgaimyAHallerF. CTNNB1 (β-catenin)-altered neoplasia: a review focusing on soft tissue neoplasms and parenchymal lesions of uncertain histogenesis. Adv Anat Pathol. 2016;23(1):1-12.
38.
Kammerer-JacquetSFThierrySCabillicF, et al.Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. Hum Pathol. 2017;59:34-40.
39.
ThwayKFloraRShahC, et al.Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36(3):462-469.
40.
ClayMRMartinezAPWeissSW, et al.MDM2 and CDK4 immunohistochemistry: should it be used in problematic differentiated lipomatous tumors?: a new perspective. Am J Surg Pathol. 2016;40(12):1647-1652.
41.
PilottiSDella TorreGMezzelaniA, et al.The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer. 2000;82(7):1271-1275.
42.
RaghavanSSPeternelSMullyTW, et al.Spitz melanoma is a distinct subset of spitzoid melanoma. Mod Pathol. 2020;33(6):1122-1134.
43.
WiesnerTHeJYelenskyR, et al.Kinase fusions are frequent in spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
44.
GaoQLiangWWFoltzSM, et al.Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23(1):227-238.e3.
45.
YoshiharaKWangQTorres-GarciaW, et al.The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845-4854.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
